Analysts Set LivaNova PLC (NASDAQ:LIVN) Target Price at $69.17

LivaNova PLC (NASDAQ:LIVN) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $69.17.

LIVN has been the topic of a number of analyst reports. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 23rd. Robert W. Baird lifted their price objective on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Mizuho cut their price objective on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a research report on Tuesday. Finally, The Goldman Sachs Group initiated coverage on shares of LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is owned by company insiders.

Institutional Trading of LivaNova

Several institutional investors and hedge funds have recently bought and sold shares of the business. KBC Group NV lifted its stake in LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company’s stock valued at $4,628,000 after acquiring an additional 56,580 shares during the period. Harbor Capital Advisors Inc. acquired a new stake in LivaNova during the 4th quarter valued at approximately $1,954,000. Diversified Trust Co lifted its stake in LivaNova by 9.5% during the 4th quarter. Diversified Trust Co now owns 16,432 shares of the company’s stock valued at $761,000 after acquiring an additional 1,425 shares during the period. Nordea Investment Management AB lifted its stake in LivaNova by 22.2% during the 4th quarter. Nordea Investment Management AB now owns 68,711 shares of the company’s stock valued at $3,188,000 after acquiring an additional 12,470 shares during the period. Finally, Central Pacific Bank Trust Division lifted its stake in LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock valued at $191,000 after acquiring an additional 720 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Trading Up 2.0 %

NASDAQ LIVN opened at $50.53 on Wednesday. The company’s 50-day simple moving average is $49.05 and its two-hundred day simple moving average is $49.97. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. LivaNova has a one year low of $43.15 and a one year high of $64.47. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of 120.31 and a beta of 1.01.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.